Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Alpelisib

First Posted Date: 2015-12-08

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT02624557

Locations: 🇺🇸
University of Miami / Clinical Research Services, Inc., Miami, Florida, United States
🇺🇸
DaVita Clinical Research-Denver, Lakewood, Colorado, United States
🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States

and more 1 locations

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

Phase 2

Terminated

Conditions: Cluster Headache - Episodic and Chronic

Interventions: Drug: SOM230
Drug: Placebo

First Posted Date: 2015-12-02

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT02619617

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

Phase 1

Completed

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Drug: Midazolam
Drug: AIN457

First Posted Date: 2015-11-18

Last Posted Date: 2020-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT02607774

Locations: 🇺🇸
Novartis Investigative Site, Norfolk, Virginia, United States

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1

Terminated

Conditions: Advanced Malignancies

Interventions: Drug: MBG453
Drug: PDR001
Drug: Decitabine

First Posted Date: 2015-11-18

Last Posted Date: 2023-12-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 252

Registration Number: NCT02608268

Locations: 🇺🇸
Sidney Kimmel CCC At JH Sidney Kimmel CCC, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Institute DFCI - Brookline, Boston, Massachusetts, United States
🇺🇸
UT M.D Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

Phase 1

Terminated

Conditions: Melanoma
Other Solid Tumors
NSCLC
Ovarian Cancer

Interventions: Drug: LXH254
Drug: PDR001

First Posted Date: 2015-11-18

Last Posted Date: 2022-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 142

Registration Number: NCT02607813

Locations: 🇺🇸
Massachusetts General Hospital MGH Cancer Center, Boston, Massachusetts, United States
🇨🇭
Novartis Investigative Site, Zuerich, Switzerland
🇳🇱
Medical Oncology, Erasmus MC, Rotterdam, Netherlands

and more 2 locations

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 2

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Investigator choice of chemotherapy
Drug: Spartalizumab

First Posted Date: 2015-11-17

Last Posted Date: 2022-02-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 122

Registration Number: NCT02605967

Locations: 🇹🇭
Novartis Investigative Site, Chiang Mai, Thailand
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Northwest Georgia Oncology Center NWGA Onc - Carrollton, Marietta, Georgia, United States

and more 2 locations

Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

Phase 1

Completed

Conditions: Follicular Lymphoma, Mantle Cell Lymphoma

Interventions: Drug: BCL201
Drug: Idelalisib

First Posted Date: 2015-11-11

Last Posted Date: 2020-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT02603445

Locations: 🇩🇪
Novartis Investigative Site, Mainz, Germany

Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: QVA149
Drug: Tiotropium
Drug: Salmeterol/fluticasone

First Posted Date: 2015-11-11

Last Posted Date: 2019-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1053

Registration Number: NCT02603393

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

Phase 1

Terminated

Conditions: Uveal Melanoma

Interventions: Drug: LXS196
Drug: LXS196 and HDM201

First Posted Date: 2015-11-10

Last Posted Date: 2022-09-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 107

Registration Number: NCT02601378

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇪🇸
Novartis Investigative Site, Madrid, Spain

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.

Phase 3

Terminated

Conditions: Myelofibrosis With High Molecular Risk Mutations

Interventions: Drug: Ruxolitinib
Drug: Ruxolitinib Placebo

First Posted Date: 2015-11-05

Last Posted Date: 2019-08-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT02598297

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy